Latest Easton Pharmaceuticals Inc (EAPH) Headlines
Post# of 451
Posted On: 03/09/2014 4:25:33 PM
Latest Easton Pharmaceuticals Inc (EAPH) Headlines
Easton Pharmaceuticals Announces Upgrade to Its Proposal With Vodis Innovative Pharmaceuticals, Signs Additional LOI and Partnership Agreement Towards Medical Marijuana Acquisition(s), Places Funds in Escrow Towards a Final Agreement and Closing
Marketwire - Mon Mar 03, 7:02AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it has revised its offer to Vodis Innovative Pharmaceuticals in the companies quest to close on an acceptable agreement towards its medical marijuana initiatives. Additionally, Easton has signed a Letter of Intent with a private Ontario Canada based company presently producing organic medical marijuana, as well as executing an additional letter of intent towards a partnership agreement for the purchase of various marijuana producing companies who have all filed applications with health Canada for medical marijuana distribution and growing licenses under the MMPR (Medical Marijuana For Medical Purposes Regulations) which includes a revenue producing acquisition.
Easton Pharmaceuticals Announces the Launching of Hempstral SA, a New Hemp Based Anti Ageing Product & Reaches Marketing Develop and Distribution Agreement With HempLifeToday.com
Marketwire - Thu Feb 27, 7:52AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces its has designed and launched its new Hemp based product, Hempstral SA, and has reached an agreement with Hemp Life Today, LLC, a wholly owned subsidiary of Global Links Corp. Hemp Life Today will assist in developing a marketing and distribution program as well as both companies jointly developing a new line of innovative Hemp based products to be marketed on the HempLifeToday.com website, for US and global distribution.
Easton Pharmaceuticals to Attend and Introduce Its New & Existing Product Line at the Total Health Show
Marketwire - Thu Feb 20, 7:39AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it will attend and present at the Total Health Show to be held on April 4,5 and 6 in Toronto, Canada.
Easton Pharmaceuticals Is in Receipt of Proposal to Increase Current Financing; Provides Other Initiative Updates
Marketwire - Mon Feb 10, 8:15AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it has received a proposal from an accredited investor to increase its financing from the current $1,000,000 per year it is eligible to currently receive and has been receiving, to $5,000,000 per year by filing a Regulation A Offering Statement with the SEC.
Easton Pharmaceutical, Inc. Analyst Report and Medical Marijuana Initiatives - by BrokerBank Securities, Inc.
PR Newswire - Mon Feb 10, 6:00AM CST
Easton Pharmaceutical, Inc. (PINKSHEETS: EAPH) is a company that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products. Easton Pharmaceuticals product "VIORRA", is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder). The world market demand for this female condition is conservatively estimated to be in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized Safe ingredients.
Easton Pharmaceuticals Signs Letter of Intent / NDA, Enters Into Negotiations With Private B.C. Company Who Has Received Federal License Approval on Medical Marijuana & Closes on Agreement to Engage Leading Legal Consultant
Marketwire - Fri Feb 07, 8:17AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces It has finalized and closed on agreement to engage a leading legal consultant on medical marijuana. Subsequent to this agreement, Easton has signed a Letter Of Intent / NDA and has entered into high level negotiations with a private company based out of British Columbia who has been approved for a medical marijuana license to grow and distribute medical marijuana throughout all of Canada.
Easton Pharmaceuticals Announces Update to VIORRA Initiative: Manufacturing Set to Begin
Marketwire - Mon Feb 03, 8:32AM CST
Easton Pharmaceuticals (OTC: EAPH) and its Consultants in Mexico, BMV Medica S.A., announce they have advanced a timetable towards a VIORRA product launch in Mexico, Latin America and potentially the US, Canada and other international markets.
TrendingWallStreet.com Releases Begins Analysis on EAPH, PHOT, CMG, and MAT
ACCESSWIRE - Sun Feb 02, 11:38PM CST
Whether it's a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Easton Pharmaceuticals Moves Towards Formerly Engaging Leading Legal Expert on Medical Marijuana Licence, as Well as Moving to Next Level of Medical Marijuana Negotiations With Request for Term-Sheet and Final Due Diligence Documents
Marketwire - Wed Jan 29, 7:02AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces It has moved to the next level of medical marijuana negotiations towards a possible investment / partnership with a private Canadian Company. In addition, Easton Pharmaceuticals is moving towards signing a contract to retain and hire a senior legal expert on Medical Marijuana in Canada to file a growers / distributorship license on behalf of Easton Pharmaceuticals.
Easton Pharmaceuticals Announces Update on Negotiations Towards Its Medical Marijuana Initiatives
Marketwire - Thu Jan 16, 7:52AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products, today announces an update to its previously announced Medical Marijuana initiatives.
Easton Pharmaceuticals Provides Update on Initiatives Towards Its Cancer Drug "Xilive" and Its Mexican Government Regulatory Filing Submission for "Viorra"
Marketwire - Wed Dec 11, 10:56AM CST
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products provides update towards its 2 main initiatives, its minority ownership interest for its early stage cancer drug "Xilive" and on its Mexican government regulatory filing For Its "Viorra" product.
Easton Pharmaceuticals Enters Into Cancer Drug Industry by Acquiring Initial Minority Ownership Interest in Experimental Cancer Drug "XILIVE" With 12 Month Option to Purchase Remaining Interest; Preliminary Feedback Extremely Promising
Marketwire - Wed Nov 06, 12:39PM CST
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products announced today It has purchased an initial 10 percent ownership interest in experimental cancer drug "XILIVE" From a private Canadian company and individual.
Gary Simpson of Windmill Capital Headlines Ivy Family Office Network Boston Forum
PRWeb - Wed Nov 06, 2:17AM CST
The Ivy Family Office Network hosted its 2014 Family Office Outlook Forum in Boston, MA on with a discussion on "Emerging Alpha Generating Strategies" led by Gary L. Simpson, co-Founder & Chief Operating Officer of Windmill Capital.
Easton Pharmaceuticals Is Provided a Manufacturing, Regulatory Filing Update and Forward Sales Estimates for VIORRA
Marketwire - Mon Nov 04, 7:30AM CST
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products announced today an update to its recently announced regulatory filing in Mexico for its Viorra product through BMV Medica S.A. de C.V. (BMV), a Mexican Regulatory & Licensing consultancy in Mexico, Latin America and South-East Asia.
Easton Pharmaceuticals Announces Formal Agreement & Advances Payment to BMV Medica S.A. Towards a Regulatory Filing in Mexico for "Viorra"; Company Anticipates Approval and Initial Sales by End of Second Quarter 2014
Marketwire - Tue Oct 22, 7:03AM CDT
Easton Pharmaceuticals, Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered drugs and therapeutic healthcare products announced today it has signed a formal agreement with BMV Medica S.A. de C.V. (BMV) a Mexican Regulatory & Licensing consultancy to begin the process of submitting applications to obtain regulatory government approvals for its flagship product "VIORRA."
Easton Pharmaceuticals Re- Enters Drug Market, Acquires 50% Ownership Interest In FSAD Drug And Related Patents / Patent Pendings. Drug Subsequently Underwent Clinical Trials At Cedar-Sinai Medical Center, Beverley Hills, CA.
Business Wire - Mon Sep 16, 8:00AM CDT
Easton Pharmaceuticals (OTC: EAPH - News), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announces It has re-entered the drug market by acquiring a 50 percent ownership interest in a Drug designed to treat (FSAD) Female Sexual Arousal Disorder (FSAD). The acquisition terms are for the issuance of 10,000,000 restricted shares of the company's common stock, previously issued in escrow and an option to purchase additional shares should the drug be developed and brought to a certain stage utilizing FDA protocols.
Easton Pharmaceuticals, Inc. Provides Update on Its Medical Marijuana Initiatives
Filing Services Canada - Fri Aug 23, 7:40AM CDT
Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, today announced updates to its Canadian and United States Medical Marijuana initiatives.
OTC Daily Alert Stock Watch - Easton Pharmaceuticals (OTC: EAPH)
WorldStockWire - Tue Aug 20, 12:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Easton Pharmaceuticals Announces It Has Ordered Ingredients towards Producing Final Test and Trial Samples of Its Re-Formulated Viorra and Other Recently Added Portfolio Products
Business Wire - Wed Aug 14, 10:57AM CDT
Easton Pharmaceuticals (OTC-PINK:EAPH - News), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announces it has ordered specialized ingredients from its various suppliers for the purpose of creating final batches, trial and test samples of its reformulated Viorra and other recently added portfolio products.
Easton Pharmaceuticals Announces Upgrade to Its Proposal With Vodis Innovative Pharmaceuticals, Signs Additional LOI and Partnership Agreement Towards Medical Marijuana Acquisition(s), Places Funds in Escrow Towards a Final Agreement and Closing
Marketwire - Mon Mar 03, 7:02AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it has revised its offer to Vodis Innovative Pharmaceuticals in the companies quest to close on an acceptable agreement towards its medical marijuana initiatives. Additionally, Easton has signed a Letter of Intent with a private Ontario Canada based company presently producing organic medical marijuana, as well as executing an additional letter of intent towards a partnership agreement for the purchase of various marijuana producing companies who have all filed applications with health Canada for medical marijuana distribution and growing licenses under the MMPR (Medical Marijuana For Medical Purposes Regulations) which includes a revenue producing acquisition.
Easton Pharmaceuticals Announces the Launching of Hempstral SA, a New Hemp Based Anti Ageing Product & Reaches Marketing Develop and Distribution Agreement With HempLifeToday.com
Marketwire - Thu Feb 27, 7:52AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces its has designed and launched its new Hemp based product, Hempstral SA, and has reached an agreement with Hemp Life Today, LLC, a wholly owned subsidiary of Global Links Corp. Hemp Life Today will assist in developing a marketing and distribution program as well as both companies jointly developing a new line of innovative Hemp based products to be marketed on the HempLifeToday.com website, for US and global distribution.
Easton Pharmaceuticals to Attend and Introduce Its New & Existing Product Line at the Total Health Show
Marketwire - Thu Feb 20, 7:39AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it will attend and present at the Total Health Show to be held on April 4,5 and 6 in Toronto, Canada.
Easton Pharmaceuticals Is in Receipt of Proposal to Increase Current Financing; Provides Other Initiative Updates
Marketwire - Mon Feb 10, 8:15AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it has received a proposal from an accredited investor to increase its financing from the current $1,000,000 per year it is eligible to currently receive and has been receiving, to $5,000,000 per year by filing a Regulation A Offering Statement with the SEC.
Easton Pharmaceutical, Inc. Analyst Report and Medical Marijuana Initiatives - by BrokerBank Securities, Inc.
PR Newswire - Mon Feb 10, 6:00AM CST
Easton Pharmaceutical, Inc. (PINKSHEETS: EAPH) is a company that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products. Easton Pharmaceuticals product "VIORRA", is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder). The world market demand for this female condition is conservatively estimated to be in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized Safe ingredients.
Easton Pharmaceuticals Signs Letter of Intent / NDA, Enters Into Negotiations With Private B.C. Company Who Has Received Federal License Approval on Medical Marijuana & Closes on Agreement to Engage Leading Legal Consultant
Marketwire - Fri Feb 07, 8:17AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces It has finalized and closed on agreement to engage a leading legal consultant on medical marijuana. Subsequent to this agreement, Easton has signed a Letter Of Intent / NDA and has entered into high level negotiations with a private company based out of British Columbia who has been approved for a medical marijuana license to grow and distribute medical marijuana throughout all of Canada.
Easton Pharmaceuticals Announces Update to VIORRA Initiative: Manufacturing Set to Begin
Marketwire - Mon Feb 03, 8:32AM CST
Easton Pharmaceuticals (OTC: EAPH) and its Consultants in Mexico, BMV Medica S.A., announce they have advanced a timetable towards a VIORRA product launch in Mexico, Latin America and potentially the US, Canada and other international markets.
TrendingWallStreet.com Releases Begins Analysis on EAPH, PHOT, CMG, and MAT
ACCESSWIRE - Sun Feb 02, 11:38PM CST
Whether it's a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Easton Pharmaceuticals Moves Towards Formerly Engaging Leading Legal Expert on Medical Marijuana Licence, as Well as Moving to Next Level of Medical Marijuana Negotiations With Request for Term-Sheet and Final Due Diligence Documents
Marketwire - Wed Jan 29, 7:02AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces It has moved to the next level of medical marijuana negotiations towards a possible investment / partnership with a private Canadian Company. In addition, Easton Pharmaceuticals is moving towards signing a contract to retain and hire a senior legal expert on Medical Marijuana in Canada to file a growers / distributorship license on behalf of Easton Pharmaceuticals.
Easton Pharmaceuticals Announces Update on Negotiations Towards Its Medical Marijuana Initiatives
Marketwire - Thu Jan 16, 7:52AM CST
Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products, today announces an update to its previously announced Medical Marijuana initiatives.
Easton Pharmaceuticals Provides Update on Initiatives Towards Its Cancer Drug "Xilive" and Its Mexican Government Regulatory Filing Submission for "Viorra"
Marketwire - Wed Dec 11, 10:56AM CST
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products provides update towards its 2 main initiatives, its minority ownership interest for its early stage cancer drug "Xilive" and on its Mexican government regulatory filing For Its "Viorra" product.
Easton Pharmaceuticals Enters Into Cancer Drug Industry by Acquiring Initial Minority Ownership Interest in Experimental Cancer Drug "XILIVE" With 12 Month Option to Purchase Remaining Interest; Preliminary Feedback Extremely Promising
Marketwire - Wed Nov 06, 12:39PM CST
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products announced today It has purchased an initial 10 percent ownership interest in experimental cancer drug "XILIVE" From a private Canadian company and individual.
Gary Simpson of Windmill Capital Headlines Ivy Family Office Network Boston Forum
PRWeb - Wed Nov 06, 2:17AM CST
The Ivy Family Office Network hosted its 2014 Family Office Outlook Forum in Boston, MA on with a discussion on "Emerging Alpha Generating Strategies" led by Gary L. Simpson, co-Founder & Chief Operating Officer of Windmill Capital.
Easton Pharmaceuticals Is Provided a Manufacturing, Regulatory Filing Update and Forward Sales Estimates for VIORRA
Marketwire - Mon Nov 04, 7:30AM CST
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products announced today an update to its recently announced regulatory filing in Mexico for its Viorra product through BMV Medica S.A. de C.V. (BMV), a Mexican Regulatory & Licensing consultancy in Mexico, Latin America and South-East Asia.
Easton Pharmaceuticals Announces Formal Agreement & Advances Payment to BMV Medica S.A. Towards a Regulatory Filing in Mexico for "Viorra"; Company Anticipates Approval and Initial Sales by End of Second Quarter 2014
Marketwire - Tue Oct 22, 7:03AM CDT
Easton Pharmaceuticals, Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered drugs and therapeutic healthcare products announced today it has signed a formal agreement with BMV Medica S.A. de C.V. (BMV) a Mexican Regulatory & Licensing consultancy to begin the process of submitting applications to obtain regulatory government approvals for its flagship product "VIORRA."
Easton Pharmaceuticals Re- Enters Drug Market, Acquires 50% Ownership Interest In FSAD Drug And Related Patents / Patent Pendings. Drug Subsequently Underwent Clinical Trials At Cedar-Sinai Medical Center, Beverley Hills, CA.
Business Wire - Mon Sep 16, 8:00AM CDT
Easton Pharmaceuticals (OTC: EAPH - News), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announces It has re-entered the drug market by acquiring a 50 percent ownership interest in a Drug designed to treat (FSAD) Female Sexual Arousal Disorder (FSAD). The acquisition terms are for the issuance of 10,000,000 restricted shares of the company's common stock, previously issued in escrow and an option to purchase additional shares should the drug be developed and brought to a certain stage utilizing FDA protocols.
Easton Pharmaceuticals, Inc. Provides Update on Its Medical Marijuana Initiatives
Filing Services Canada - Fri Aug 23, 7:40AM CDT
Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, today announced updates to its Canadian and United States Medical Marijuana initiatives.
OTC Daily Alert Stock Watch - Easton Pharmaceuticals (OTC: EAPH)
WorldStockWire - Tue Aug 20, 12:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Easton Pharmaceuticals Announces It Has Ordered Ingredients towards Producing Final Test and Trial Samples of Its Re-Formulated Viorra and Other Recently Added Portfolio Products
Business Wire - Wed Aug 14, 10:57AM CDT
Easton Pharmaceuticals (OTC-PINK:EAPH - News), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announces it has ordered specialized ingredients from its various suppliers for the purpose of creating final batches, trial and test samples of its reformulated Viorra and other recently added portfolio products.
(0)
(0)Easton Pharmaceuticals Inc (EAPH) Stock Research Links
Scroll down for more posts ▼